We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock
ONCT

Delisted

ONCT was delisted on the 2nd of December, 2024.

Back to rankings

1 hedge funds and large institutions have $74 invested in Oncternal Therapeutics, Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBP
Union Bancaire Privee
Switzerland
+$74

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
UBP
1
Union Bancaire Privee
Switzerland
$74 +$74 +175 New

ONCT Hedge Fund Activity: Q2 2025 in Review

1 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q2 2025, worth a combined $74.

Buyers outnumbered sellers: 1 fund opened new ONCT positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Union Bancaire Privee, opening a new position worth an estimated $74.

  • 1 institutional investor held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q2 2025, up from 0 in Q1 2025.
  • Funds reported $74 of Oncternal Therapeutics, Inc. Common Stock stock for Q2 2025.
  • 1 fund opened new Oncternal Therapeutics, Inc. Common Stock positions in Q2 2025 and 0 closed out, a net change of +1 holder.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q2 2025 was Union Bancaire Privee, an estimated $74 added.

Based on aggregated 13F filings for Q2 2025.